Cargando…

T Cells and CDDO-Me Attenuate Immunosuppressive Activation of Human Melanoma-Conditioned Macrophages

Melanoma tumors are highly immunogenic, making them an attractive target for immunotherapy. However, many patients do not mount robust clinical responses to targeted therapies, which is attributable, at least in part, to suppression of immune responses by tumor-associated macrophages (TAMs) in the t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Torres, Gretel M., Yang, Heetaek, Park, Chanhyuk, Spezza, Paul A., Khatwani, Nikhil, Bhandari, Rajan, Liby, Karen T., Pioli, Patricia A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898828/ https://www.ncbi.nlm.nih.gov/pubmed/35265066 http://dx.doi.org/10.3389/fimmu.2022.768753

Ejemplares similares

CDDO-Me Alters the Tumor Microenvironment in Estrogen Receptor Negative Breast Cancer
por: Ball, Michael S., et al.
Publicado: (2020)

CDDO-Me Redirects Activation of Breast Tumor Associated Macrophages
por: Ball, Michael S., et al.
Publicado: (2016)

Synthesis and Anticancer Activity of CDDO and CDDO-Me, Two Derivatives of Natural Triterpenoids
por: Borella, Rebecca, et al.
Publicado: (2019)

The synthetic triterpenoids CDDO-TFEA and CDDO-Me, but not CDDO, promote nuclear exclusion of BACH1 impairing its activity
por: Casares, Laura, et al.
Publicado: (2022)

The Triterpenoid CDDO-Methyl Ester Redirects Macrophage Polarization and Reduces Lung Tumor Burden in a Nrf2-Dependent Manner
por: Moerland, Jessica A., et al.
Publicado: (2023)

CDDO-Me: A Novel Synthetic Triterpenoid for the Treatment of Pancreatic Cancer
por: Deeb, Dorrah, et al.
Publicado: (2010)

The Triterpenoid CDDO-Me Inhibits Bleomycin-Induced Lung Inflammation and Fibrosis
por: Kulkarni, Ajit A., et al.
Publicado: (2013)

CDDO-Me inhibits tumor growth and prevents recurrence of pancreatic ductal adenocarcinoma
por: GAO, XIAOHUA, et al.
Publicado: (2015)

Preclinical evidences toward the use of triterpenoid CDDO-Me for solid cancer prevention and treatment
por: Wang, Yan-Yang, et al.
Publicado: (2014)

CDDO-Me reveals USP7 as a novel target in ovarian cancer cells
por: Qin, Dongjun, et al.
Publicado: (2016)

A Synthetic Triterpenoid CDDO-Im Inhibits Tumorsphere Formation by Regulating Stem Cell Signaling Pathways in Triple-Negative Breast Cancer
por: So, Jae Young, et al.
Publicado: (2014)

Inhibition of Telomerase Activity by Oleanane Triterpenoid CDDO-Me in Pancreatic Cancer Cells is ROS-Dependent
por: Deeb, Dorrah, et al.
Publicado: (2013)

Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties
por: Wang, Yan-Yang, et al.
Publicado: (2014)

CDDO-Me Protects Normal Lung and Breast Epithelial Cells but Not Cancer Cells from Radiation
por: El-Ashmawy, Mariam, et al.
Publicado: (2014)

Neuroprotective Effects of the Triterpenoid, CDDO Methyl Amide, a Potent Inducer of Nrf2-Mediated Transcription
por: Yang, Lichuan, et al.
Publicado: (2009)

CDDO-Me Selectively Attenuates CA1 Neuronal Death Induced by Status Epilepticus via Facilitating Mitochondrial Fission Independent of LONP1
por: Kim, Ji-Eun, et al.
Publicado: (2019)

Prevention of Prostate Cancer with Oleanane Synthetic Triterpenoid CDDO-Me in the TRAMP Mouse Model of Prostate Cancer
por: Gao, Xiaohua, et al.
Publicado: (2011)

Telomerase Reverse Transcriptase (TERT) is a Therapeutic Target of Oleanane Triterpenoid CDDO-Me in Prostate Cancer
por: Liu, Yongbo, et al.
Publicado: (2012)

Induction of Apoptosis in Pancreatic Cancer Cells by CDDO-Me Involves Repression of Telomerase through Epigenetic Pathways
por: Deeb, Dorrah, et al.
Publicado: (2014)

Hsp90 Is a Novel Target Molecule of CDDO-Me in Inhibiting Proliferation of Ovarian Cancer Cells
por: Qin, Dong-Jun, et al.
Publicado: (2015)

CDDO-Me Attenuates Clasmatodendrosis in CA1 Astrocyte by Inhibiting HSP25-AKT Mediated DRP1-S637 Phosphorylation in Chronic Epilepsy Rats
por: Lee, Duk-Shin, et al.
Publicado: (2022)

Prevention and Treatment of Experimental Estrogen Receptor – Negative Mammary Carcinogenesis by the Synthetic Triterpenoid CDDO-Methyl Ester and the Rexinoid LG100268
por: Liby, Karen, et al.
Publicado: (2008)

Bardoxolone-Methyl (CDDO-Me) Impairs Tumor Growth and Induces Radiosensitization of Oral Squamous Cell Carcinoma Cells
por: Hermann, Cornelius, et al.
Publicado: (2021)

The Triterpenoid Nrf2 Activator, CDDO-Me, Decreases Neutrophil Senescence in a Murine Model of Joint Damage
por: Amirova, Kristiana M., et al.
Publicado: (2023)

CDDO-Me Attenuates Vasogenic Edema and Astroglial Death by Regulating NF-κB p65 Phosphorylations and Nrf2 Expression Following Status Epilepticus
por: Kim, Min-Ju, et al.
Publicado: (2019)

Oleanane triterpenoid CDDO-Me induces apoptosis in multidrug resistant osteosarcoma cells through inhibition of Stat3 pathway
por: Ryu, Keinosuke, et al.
Publicado: (2010)

The novel Nrf2 activator CDDO‐EA attenuates cerebral ischemic injury by promoting microglia/macrophage polarization toward M2 phenotype in mice
por: Lei, Xia, et al.
Publicado: (2020)

CDDO-Me Attenuates CA1 Neuronal Death by Facilitating RalBP1-Mediated Mitochondrial Fission and 4-HNE Efflux in the Rat Hippocampus Following Status Epilepticus
por: Kim, Ji-Eun, et al.
Publicado: (2022)

CDDO-Me Abrogates Aberrant Mitochondrial Elongation in Clasmatodendritic Degeneration by Regulating NF-κB-PDI-Mediated S-Nitrosylation of DRP1
por: Lee, Duk-Shin, et al.
Publicado: (2023)

Induction of Mitosis Delay and Apoptosis by CDDO-TFEA in Glioblastoma Multiforme
por: Tsai, Tai-Hsin, et al.
Publicado: (2021)

BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment
por: Liu, Wei, et al.
Publicado: (2022)

CDDO and ATRA Instigate Differentiation of IMR32 Human Neuroblastoma Cells
por: Chaudhari, Namrata, et al.
Publicado: (2017)

Ca(2+) influx-mediated dilation of the endoplasmic reticulum and c-FLIP(L) downregulation trigger CDDO-Me–induced apoptosis in breast cancer cells
por: Jeong, Soo Ah, et al.
Publicado: (2015)

Bardoxolone-Methyl (CDDO-Me) Suppresses Androgen Receptor and Its Splice-Variant AR-V7 and Enhances Efficacy of Enzalutamide in Prostate Cancer Cells
por: Khurana, Namrata, et al.
Publicado: (2020)

Structure of the BTB Domain of Keap1 and Its Interaction with the Triterpenoid Antagonist CDDO
por: Cleasby, Anne, et al.
Publicado: (2014)

CDDO-Me Inhibits Microglial Activation and Monocyte Infiltration by Abrogating NFκB- and p38 MAPK-Mediated Signaling Pathways Following Status Epilepticus
por: Kim, Ji-Eun, et al.
Publicado: (2020)

Triterpenoid CDDO-Me induces ROS generation and up-regulates cellular levels of antioxidative enzymes without induction of DSBs in human peripheral blood mononuclear cells
por: Beinke, Christina, et al.
Publicado: (2020)

A Point Mutation at C151 of Keap1 of Mice Abrogates NRF2 Signaling, Cytoprotection in Vitro, and Hepatoprotection in Vivo by Bardoxolone Methyl (CDDO-Me)
por: Gatbonton-Schwager, Tonibelle, et al.
Publicado: (2023)

CDDO-Me Attenuates Astroglial Autophagy via Nrf2-, ERK1/2-SP1- and Src-CK2-PTEN-PI3K/AKT-Mediated Signaling Pathways in the Hippocampus of Chronic Epilepsy Rats
por: Kim, Ji-Eun, et al.
Publicado: (2021)

Immunosuppressive activity is attenuated by Astragalus polysaccharides through remodeling the gut microenvironment in melanoma mice
por: Ding, Guiqing, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kmklbk47glu1b59r4p4rhnbmm1